文献速递免疫规划慢病防控与筛查

多发性硬化患者接受疾病修饰治疗时季节性流感疫苗与肺炎球菌多糖疫苗的免疫原性:单中心前瞻性研究

Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
PubMed 文献 · Vaccine · 2024-05-24

该单中心前瞻性研究纳入172例多发性硬化患者,接种四价流感灭活疫苗和23价肺炎球菌多糖疫苗后4周检测抗体。流感A和B抗体滴度显著升高,而抗PPSV23血清阳性率无差异。利妥昔单抗与较低抗体滴度相关,未报告严重不良事件或疫苗相关复发。

要点

  • 接种流感疫苗后4周流感A和B血清阳性率较基线显著升高(P<0.001)。
  • 接种PPSV23后4周抗PPSV23血清阳性率与基线无差异(37.1%)。
  • 利妥昔单抗与较低的流感抗体滴度相关,干扰素和富马酸未影响血清转化。

核心结论

  • 接受治疗的多发性硬化患者接种流感疫苗后的血清转化率高于接种PPSV23。
  • 利妥昔单抗影响免疫应答的高度。
  • 需要提高免疫接种覆盖率,并未来评估免疫接种所引发的免疫应答广度。

研究设计与样本

  • 单中心前瞻性研究,纳入2019年11月至2020年3月期间同意接种的成人多发性硬化患者。
  • 所有患者接种单剂四价流感灭活疫苗和23价肺炎球菌多糖疫苗。
  • 接种前和接种后4周采集血样检测流感A、B和肺炎链球菌抗体。
  • 随访12个月记录不良事件和多发性硬化复发。

主要发现

  • 共纳入172例患者(女性65.7%,平均年龄42±13岁,平均多发性硬化病程7.6±7.2年,81.4%接受疾病修饰治疗)。
  • 151例患者有抗体检测结果。
  • 抗PPSV23血清阳性率在基线和随访4周时无差异(n=56,37.1%)。
  • 接种后流感A和B绝对抗体滴度显著升高(p<0.001)。
  • 流感A血清阳性率在4周时为57例(37.7%),基线为19例(12.6%)(pMcNemar<0.001);流感B血清转化在4周时为110例(72.8%),基线为12例(7.9%)(pMcNemar<0.001)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为需要提高这些患者的免疫接种覆盖率,并未来评估免疫接种所引发的免疫应答广度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunogenicity of influenza and pneumococcal vaccines varies and requires further elucidation in patients with multiple sclerosis (MS) under treatment with disease-modifying therapies (DMTs). METHODS: Adult MS patients who consented with vaccination after standard-of-care consultation by their treating physicians were enrolled. All received a single dose of an inactivated quadrivalent influenza vaccine and of the 23-valent pneumococcal vaccine. A blood sample was collected before and after four weeks of vaccination for measurement of antibodies against Influenza A, B and S. pneumoniae. Patients were followed-up for adverse events and MS relapse for 12 months. RESULTS: One hundred and seventy-two patients (65.7 % female, mean age 42 ± 13 years old, mean MS duration 7.6 ± 7.2 years, 81.4 % under DMTs) were enrolled from November 2019 to March 2020. Antibody measurements were available for 151 patients. Seropositivity for anti-PPSV23 did not differ between baseline and at 4 weeks of follow-up (n = 56, 37.1 %). There was a significant increase of absolute antibody titers post-vaccination for both influenza A and B (p < 0.001). For Influenza A, seropositivity was evident for 57 (37.7 %) patients at 4 weeks compared to 19 (12.6 %) patients at baseline (pMcNemar < 0.001). For Influenza Β, 110 (72.8 %) seroconverted 4 weeks after vaccination compared to 12 (7.9 %) at baseline (pMcNemar < 0.001). Interferon and fumarate did not affect influenza seroconversion while rituximab was associated with lower titers. Mild local AEs (pain, edema) were observed in 23.8 %; no severe AE was reported. Thirty-four patients (19.8 %) had a relapse during the 12-month follow-up; none was attributed to the vaccination. CONCLUSIONS: Seroconversion in MS patients on treatment was more frequent following influenza compared to PPSV23 vaccination. Rituximab had an effect on the height of the immune response. Better immunization coverage as well as future evaluation of the breadth of immune response elicited by immunization is necessary for these patients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Marantos T, Kyriazopoulou E, Angelakis E, et al. Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study. Vaccine. 2024. PMID: 38796324. doi:10.1016/j.vaccine.2024.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。